TB Biomarker Panel for Active Latent Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for tuberculosis are suboptimal, struggling to differentiate between active and latent TB, especially in immunocompromised individuals, and lack effective tools for monitoring treatment response, leading to challenges in rapid diagnosis and antibiotic resistance management.
Innovation Solution
A biomarker panel comprising CD14, CD25, IFN gamma, IL-10, CD22, CXCL10, CD64, and others is used for differential diagnosis between active and latent TB, and to monitor treatment efficacy, utilizing in vitro assays and biosensors for accurate detection and quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods (culture, PCR, imaging, skin tests) are used for tuberculosis diagnosis, then definitive diagnosis can be achieved, but the process is slow (3-12 weeks for culture), requires invasive sampling, or lacks ability to differentiate active from latent TB
Solution Approach 1:
The patent changes the diagnostic parameter from detecting Mycobacterium tuberculosis itself (culture, PCR) to detecting host immune response biomarkers (cytokines, chemokines, antibodies). This parameter shift enables rapid detection within hours rather than weeks, while maintaining diagnostic accuracy through measurement of immune system activation patterns specific to active TB infection
Solution Approach 2:
The patent uses host immune response molecules (cytokines, chemokines, antibodies) as intermediary markers that mediate between the pathogen and the diagnostic detection system. These biomarkers serve as proxies that indicate active TB infection without requiring direct detection of the slow-growing Mycobacterium tuberculosis organism, thus resolving the time delay in diagnosis
2Measurement precision
If current diagnostic tools are used, then tuberculosis cases can be identified, but they cannot effectively differentiate between active and latent tuberculosis, especially in immunocompromised individuals
Solution Approach 1:
The patent segments the immune response into multiple distinct biomarker categories (cytokines, chemokines, antibodies, soluble receptors) and measures them in combination. This segmentation allows differentiation of active TB from latent TB by identifying specific patterns of immune activation, and maintains effectiveness in immunocompromised patients whose overall immune response may be blunted but still produce distinguishable biomarker profiles
Solution Approach 2:
The patent employs a composite diagnostic approach using multiple biomarkers in combination rather than relying on a single test. This composite biomarker panel creates a more robust diagnostic signature that can differentiate active from latent TB with higher precision and maintains adaptability across different patient populations including immunocompromised individuals
3Measurement precision
If invasive sampling methods are used for extrapulmonary TB, then appropriate samples containing Mycobacterial DNA can be obtained for PCR, but the procedure is costly and involves additional patient risks
Solution Approach 1:
The patent extracts the diagnostic target from Mycobacterium tuberculosis itself to the host's immune response biomarkers that are present in easily accessible body fluids like blood or serum. This extraction eliminates the need for invasive sampling procedures required to obtain adequate Mycobacterial DNA for PCR, thereby reducing patient risk and procedural cost while maintaining diagnostic sensitivity through detection of immune activation patterns
4Productivity
If empirical anti-microbial chemotherapy is commenced based on clinical suspicion, then treatment can be started without waiting for definitive diagnosis, but transmission is not effectively curtailed and antibiotic resistance may develop
Solution Approach 1:
The patent enables preliminary action by providing a rapid diagnostic test that can be performed within hours rather than weeks. This allows clinicians to confidently initiate appropriate anti-TB chemotherapy immediately after rapid biomarker testing, eliminating the need for empirical treatment delays while ensuring transmission curtailment through timely effective therapy based on confirmed active TB diagnosis
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to biomarkers for diagnosing, monitoring and/or treating tuberculosisin both immunocompetent and immunocompromised individuals with or without co-infection with HIV, monitoring the responses of individuals to anti- mycobacterial chemotherapy, monitoring the progression of latent tuberculosis to active tuberculosis, differentiatingactive tuberculosis from latent tuberculosis, and from other clinical conditions that mimic tuberculosis (TB).The invention also relates to methods fordiagnosing, monitoring and/or treating tuberculosis using said biomarkers.The above pertain in all aspects both to pulmonary and extrapulmonary Mycobacterium tuberculosisinfections, with Mycobacterium tuberculosisbeing the causative organism in tuberculosis. The invention therefore finds great utility in assisting with future drug discovery efforts for tuberculosis and also provides proxy clinical end points as well as being an effective predictor of a response to treatment.